Form 4: Y-mAbs Therapeutics SVP Sells Shares to Cover Tax Obligations

Susan Laura Smith, SVP & Chief Commercial Officer of Y-mAbs Therapeutics, sold 1,682 shares of common stock on March 5, 2024, to cover tax liabilities associated with vesting restricted stock units.

Summary

• On March 5, 2024, Susan Laura Smith, the SVP & Chief Commercial Officer of Y-mAbs Therapeutics, sold 1,682 shares of the company's common stock.
• The sale was executed at a price of $16.55 per share.
• The transaction was a non-discretionary sale to cover tax liabilities related to the vesting and settlement of restricted stock units.
• Following the transaction, Smith directly owns 33,918 shares of Y-mAbs Therapeutics.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine transaction to cover tax obligations. It doesn't necessarily reflect a positive or negative view of the company's prospects.

Industry Context

This is a routine Form 4 filing, indicating an insider transaction. It's common for executives to sell shares to cover tax obligations when restricted stock units vest. These transactions are closely monitored but don't necessarily indicate a negative outlook for the company.

Stakeholder Impact

• The sale has a minimal impact on shareholders as it's a small transaction by an individual officer.

Key Dates